# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G/A**

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

Unicycive Therapeutics, Inc.				
		(Name of Issuer)		
		Common Stock		
		(Title of Class of Securities)		
		90466Y103		
		(CUSIP Number)		
		December 31, 2021 (Date of Event Which Requires Filing of this Statement)		
Check the ann	propriate box to	designate the rule pursuant to which this Schedule is filed:		
	le 13d-1(b)	acsignate the full pursuant to which this schedule is filed.		
□ Ku	154-1(0)			
⊠ Ru	le 13d-1(c)			
□ Rui	le 13d-1(d)			
		this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any		
		ning information which would alter the disclosures provided in a prior cover page.		
		ne remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or		
otherwise sub	ject to the habil	ties of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).		
		Page 2 of 8		
CUSIP No.	90466Y	_		
1	NAME OF R	EPORTING PERSONS		
	Altium Capita	ll Management, LP		
		IFICATION NO. OF ABOVE PERSONS		
2	`	NLY) EIN: 82-2066653  APPROPRIATE BOX IF A MEMBER OF A GROUP		
_	CHECK THE	APPROPRIATE BOX IF A MEMBER OF A GROUP (a) $\square$ (b) X		
3	SEC USE ON	LY		
4	CITIZENSHI	P OR PLACE OF ORGANIZATION		
Delaware, United States of America		ited States of America		
	Belaware, or	SOLE VOTING		
		5 0		
	BER OF ARES	SHARED VOTING POWER		
BENEF	TCIALLY	6 176,000 Common Stock issuable upon exercise of Warrants		
OWNED BY EACH REPORTING PERSON WITH:		SOLE DISPOSITIVE POWER		
		7 0		
		SHARED DISPOSITIVE POWER		
		8 176,000 Common Stock issuable upon exercise of Warrants		
9	AGGREGAT	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
		non Stock issuable upon exercise of Warrants		

10	CHECK BOX	X IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
	1.2% <sup>(1)</sup>						
12		EPORTING PERSON					
	IA, PN						
		552 shares of Common Stock outstanding as of November 10, 2021, as set forth in the Issuer's Form 10-Q filed with the Secur wember 12, 2021.	ities and Exchange				
			Page 3 of 8				
CUSIP No.	90466Y1	7103					
1	NAME OF REPORTING PERSONS Altium Growth Fund, LP  I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) EIN: 82-2105101						
2	,	E APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆				
3	SEC USE ON	NLY	(b) X				
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
7	Delaware, United States of America						
NIIIMI		SOLE VOTING  5  0					
SHA BENEF	BER OF ARES ICIALLY ED BY	6 SHARED VOTING POWER 176,000 Common Stock issuable upon exercise of Warrants					
E <i>A</i> REPO	ACH RTING RSON	SOLE DISPOSITIVE POWER  7					
WI	WITH:  SHARED DISPOSITIVE POWER  176,000 Common Stock issuable upon exercise of Warrants						
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  176,000 Common Stock issuable upon exercise of Warrants						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES						
11		OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	1.2% <sup>(1)</sup> TYPE OF REPORTING PERSON						
	PN						
(1) Raca		52 shares of Common Stock outstanding as of November 10, 2021, as set forth in the Issuer's Form 10-O filed with the Secu	rities and Evolunge				

<sup>(1)</sup> Based on 14,9/2,552 shares of Common Stock outstanding as of November 10, 2021, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

1	NAME OF REFORTING LEASONS					
	Altium Growth GP, LLC					
			ION NO. OF ABOVE PERSONS			
	`		IN: 82-2086430			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
3	(b) X					
_	SEC USE ONLY					
4	CITIZENSHI	P OR PL	ACE OF ORGANIZATION			
	Delaware, United States of America					
			SOLE VOTING			
		5	0			
	BER OF ARES		SHARED VOTING POWER			
	CIALLY	6	SIMMED FORMOTOWER			
	ED BY		176,000 Common Stock issuable upon exercise of Warrants			
	.CH RTING	7	SOLE DISPOSITIVE POWER			
	SON		0			
WI	TH:		SHARED DISPOSITIVE POWER			
		8	176,000 Common Stock issuable upon exercise of Warrants			
9						
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	176,000 Common Stock issuable upon exercise of Warrants					
10	CHECK BOX	IF THE .	AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
	(1)					
	$1.2\%^{(1)}$					
12	TYPE OF REPORTING PERSON					
	00					

(1) Based on 14,972,552 shares of Common Stock outstanding as of November 10, 2021, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 5 of 8

CUSIP No. 90466Y103

Item 1(a). Name of Issuer: Unicycive Therapeutics, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices: 5150 El Camino Real, Suite A-32
Los Altos, CA 94022

#### Item 2(a). Name of Person Filing:

This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the "Fund"), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of the Issuer.

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the reporting persons is 152 West 57th Street, FL 20, New York, NY 10019

Item 2(c).	Citizenship: See Item 4 on the cover page(s) hereto.					
Item 2(d).	Title of Class of Securities: Common Stock, par value \$0.001 per share ("Common Stock")					
Item 2(e).	CUSIP Number: 90466Y103					
Item 3.	If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:					
	(a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780).					
	(b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).					
	Page 6 of 8					
CUSIP No.	90466Y103					
	(c) $\square$ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).					
	(d)   Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).					
	(e) $\square$ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);					
	(f) $\square$ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);					
	(g) $\square$ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);					
	(h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);					
	(i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);					
	(j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).					
Item 4.	Ownership.					
	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.					
	The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 14,972,552 shares of Common Stock outstanding as of November 10, 2021, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021					
	Page 7 of 8					
CUSIP No .	90466Y103					
Item 5.	Ownership of Five Percent or Less of a Class.					
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]					

**Ownership of More than Five Percent on Behalf of Another Person.**Not applicable Item 6.

# Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable

#### Item 8. Identification and Classification of Members of the Group.

Not applicable

#### Item 9. Notice of Dissolution of Group.

Not applicable

#### Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2022

#### Altium Capital Management, LP

By: /s/ Jacob Gottlieb
Name: Jacob Gottlieb

Title: CEO

#### Altium Growth Fund, LP

By: Altium Growth GP, LLC

Its: General Partner

Signature: /s/ Jacob Gottlieb

Name: Jacob Gottlieb

Title: Managing Member of Altium Growth GP, LLC

### Altium Growth GP, LLC

By: /s/ Jacob Gottlieb

Name: Jacob Gottlieb
Title: Managing Member

Page 8 of 8

#### EXHIBIT INDEX

EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

Members of Group

Unicycive Therapeutics, Inc SC 13G/A

#### EXHIBIT 1

# JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: February 11, 2022

### Altium Capital Management, LP

By: /s/ Jacob Gottlieb
Name: Jacob Gottlieb

Title: CEO

#### Altium Growth Fund, LP

By: Altium Growth GP, LLC

Its: General Partner

Signature: /s/ Jacob Gottlieb

Name: Jacob Gottlieb

Title: Managing Member of Altium Growth GP, LLC

### Altium Growth GP, LLC

By: /s/ Jacob Gottlieb

Name: Jacob Gottlieb
Title: Managing Member